Skip to content
10-K

Annual Report

TG THERAPEUTICS, INC. TGTX

0001437749-25-005908

← back to feed
Filed
Mar 3, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Feb 25, 2025 157.07M sh
Long Term Debt FY 2024 · Dec 31, 2023 $100.12M
Short Term Investments FY 2024 · Dec 31, 2023 $124.58M
Current Liabilities FY 2024 · Dec 31, 2023 $53.72M
Total Liabilities FY 2024 · Dec 31, 2023 $169.09M
Current Assets FY 2024 · Dec 31, 2023 $317.94M
Total Assets FY 2024 · Dec 31, 2023 $329.59M
Shares Diluted FY 2024 · Dec 31, 2022 135.41M sh
Capex FY 2024 · Dec 31, 2022 $14K
Operating Cash Flow FY 2024 · Dec 31, 2022 −$176.17M
Cash And Equivalents FY 2024 · Dec 31, 2022 $102.3M
Eps Diluted restated FY 2024 · Dec 31, 2022 −$1.65
Eps Basic restated FY 2024 · Dec 31, 2022 −$1.65
Sga Expense restated FY 2024 · Dec 31, 2022 $95.48M
Rd Expense FY 2024 · Dec 31, 2022 $125.35M
Net Income restated FY 2024 · Dec 31, 2022 −$223.81M
Operating Income restated FY 2024 · Dec 31, 2022 −$218.32M
Revenue FY 2024 · Dec 31, 2022 $2.79M
Stockholders Equity FY 2024 · Dec 31, 2021 $237.15M